Investor Overview

Stock Information
Loading data...

Shares outstanding

82.4 million (as of 8/3/2022)

Press Releases
Aug 10, 2022

Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: Date: Thursday, August 11, 2022 Time: 5:00 p.m. ET (2:00 p.m. PT) Live call: (877) 445-9755 (U.S. toll-free) or (201)...

Aug 4, 2022

-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter -- -- Reduced operating expense by 8% and improved loss from operations by 16%...

Aug 3, 2022

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The...

Aug 1, 2022

-- Top-line readout of data expected in October 2022 -- -- U.S. regulatory submission planned for the first half of 2023 -- -- Phexxi may become the first-ever woman-controlled prophylactic for...

Jul 29, 2022

Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The Company is evaluating Phexxi for two potential new indications: the prevention of urogenital chlamydia and gonorrhea in women. Top-line results are expected from its registrational Phase 3 clinical trial, EVOGUARD, in October 2022. Positive outcomes could support sNDA submissions to the FDA for these potential new indications in the first half of 2023, with an anticipated PDUFA date in the second half of 2023 due to the expedited review afforded by the Fast Track designations granted for these indications.

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem. The opportunity is expected to increase significantly if we are successful in adding the prevention of chalmydia and gonorrhea to the Phexxi label.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Effective August 11, 2022, EVFM common stock will trade on the OTC Markets Group platform. 

Featured Event
Monday, October 24, 2022 - Wednesday, October 26, 2022

"Pregnancies by Acts of Intercourse with Vaginal pH Modulator: Results from the AMPOWER Study," will be given an oral presentation during the American Society for Reproductive Medicine (ASRM) 2022...

View All

Latest Financial Results

Q1 2022, Ended March 31, 2022

Earnings Release
Earnings Call
10-Q Filing